CORT Corcept Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CORT

Price (delayed)

$17.59

Market cap

$2.04B

P/E Ratio

20.94

Dividend/share

N/A

EPS

$0.84

Enterprise value

$1.95B

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® ...

Highlights
Corcept Therapeutics's debt has shrunk by 56% YoY and by 25% QoQ
The P/E is 33% less than the 5-year quarterly average of 31.2 and 17% less than the last 4 quarters average of 25.2
The EPS has declined by 15% year-on-year and by 2.3% since the previous quarter
The quick ratio is down by 14% year-on-year and by 10% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.corcept.com
Peers: JNJ BMY LLY PFE

Key stats

What are the main financial stats of CORT
Market
Shares outstanding
115.93M
Market cap
$2.04B
Enterprise value
$1.95B
Valuations
Price to earnings (P/E)
20.94
Price to book (P/B)
3.93
Price to sales (P/S)
5.96
EV/EBIT
18.21
EV/EBITDA
17.78
EV/Sales
5.67
Earnings
Revenue
$343.09M
EBIT
$106.81M
EBITDA
$109.44M
Free cash flow
$133.88M
Per share
EPS
$0.84
Free cash flow per share
$1.15
Book value per share
$4.48
Revenue per share
$2.95
TBVPS
$4.89
Balance sheet
Total assets
$568.48M
Total liabilities
$45.81M
Debt
$1.56M
Equity
$522.68M
Working capital
$365.87M
Liquidity
Debt to equity
0
Current ratio
9.06
Quick ratio
8.76
Net debt/EBITDA
-0.86
Margins
EBITDA margin
31.9%
Gross margin
98.5%
Net margin
28.4%
Operating margin
31.1%
Efficiency
Return on assets
17.5%
Return on equity
19.1%
Return on invested capital
23.7%
Return on capital employed
20.4%
Return on sales
31.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CORT stock price

How has the Corcept Therapeutics stock price performed over time
Intraday
-1.9%
1 week
-9.7%
1 month
-14.78%
1 year
-1.18%
YTD
-32.76%
QTD
-10.62%

Financial performance

How have Corcept Therapeutics's revenue and profit performed over time
Revenue
$343.09M
Gross profit
$337.97M
Operating income
$106.81M
Net income
$97.61M
Gross margin
98.5%
Net margin
28.4%
Corcept Therapeutics's operating income has decreased by 24% YoY and by 3% from the previous quarter
The operating margin has contracted by 22% YoY and by 4% from the previous quarter
CORT's net income is down by 14% YoY
Corcept Therapeutics's net margin has decreased by 13% YoY and by 2.7% QoQ

Growth

What is Corcept Therapeutics's growth rate over time

Valuation

What is Corcept Therapeutics stock price valuation
P/E
20.94
P/B
3.93
P/S
5.96
EV/EBIT
18.21
EV/EBITDA
17.78
EV/Sales
5.67
The P/E is 33% less than the 5-year quarterly average of 31.2 and 17% less than the last 4 quarters average of 25.2
The EPS has declined by 15% year-on-year and by 2.3% since the previous quarter
The stock's price to book (P/B) is 57% less than its 5-year quarterly average of 9.2 and 23% less than its last 4 quarters average of 5.1
The company's equity rose by 15% YoY and by 2.3% QoQ
CORT's P/S is 27% below its 5-year quarterly average of 8.2 and 21% below its last 4 quarters average of 7.5
The revenue has declined by 2.3% year-on-year

Efficiency

How efficient is Corcept Therapeutics business performance
CORT's ROIC is down by 43% year-on-year and by 4.4% since the previous quarter
The return on equity has declined by 34% year-on-year and by 5% since the previous quarter
CORT's return on assets is down by 34% year-on-year and by 4.9% since the previous quarter
The return on sales has declined by 22% year-on-year and by 4% since the previous quarter

Dividends

What is CORT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CORT.

Financial health

How did Corcept Therapeutics financials performed over time
The quick ratio is down by 14% year-on-year and by 10% since the previous quarter
The company's total assets rose by 14% YoY and by 2.9% QoQ
Corcept Therapeutics's debt is 100% lower than its equity
CORT's debt to equity has shrunk by 100% YoY
Corcept Therapeutics's debt has shrunk by 56% YoY and by 25% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.